Anixa Biosciences, Inc.

Anixa Biosciences to Present Novel Ovarian Cancer CAR-T Therapy Data at ASCO 2025

2 months ago

• Anixa Biosciences will present Phase 1 clinical trial data on its innovative ovarian cancer CAR-T therapy at the 2025 ASCO Annual Meeting in Chicago, featuring a unique chimeric endocrine receptor-T cell technology. • The company's novel approach targets the follicle-stimulating hormone receptor (FSHR) on ovarian cancer cells, differentiating it from traditional CAR-T therapies by utilizing the natural ligand FSH rather than antibody fragments. • Dr. Robert Wenham from Moffitt Cancer Center, the principal investigator, will lead the presentation, highlighting Anixa's strategic collaborations with premier research institutions to advance next-generation immunotherapies for solid tumors.

Beam Therapeutics Reports Breakthrough in Alpha-1 Antitrypsin Deficiency Treatment with BEAM-302 Base Editing Therapy

2 months ago

• Beam Therapeutics' BEAM-302 demonstrated the first-ever clinical genetic correction of the disease-causing PiZ mutation in Alpha-1 Antitrypsin Deficiency patients, with a single dose producing durable increases in functional AAT protein. • The highest dose level (60mg) achieved mean total AAT of 12.4μM, exceeding the protective therapeutic threshold of 11μM, while reducing harmful mutant Z-AAT by up to 78% in circulation. • BEAM-302 showed a favorable safety profile with no serious adverse events across all dose levels, supporting continued dose escalation with updated data expected in the second half of 2025.

CAR T-cell Therapy Pipeline Surges with 180+ Companies Advancing Novel Cancer Treatments

3 months ago

• The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development. • Recent breakthroughs include Hemogenyx's first human administration of HG-CT-1 for acute myeloid leukemia and NICE's approval of lisocabtagene maraleucel for large B-cell lymphoma treatment. • Strategic industry developments are accelerating progress, with companies like CARsgen Therapeutics forming alliances to advance allogeneic CAR-T products and multiple firms reporting successful trial milestones.

Protocol Amendment Expands Anixa's Ovarian Cancer CAR-T Trial: Second Dosing and New Cancer Types Added

3 months ago

• Anixa Biosciences and Moffitt Cancer Center receive approval for protocol amendment allowing second CAR-T doses in their ovarian cancer clinical trial, enhancing potential treatment benefits. • The amended protocol expands patient eligibility to include rare ovarian cancer types such as sex cord-stromal tumors and Sertoli Leydig cell tumors. • This development eliminates the need for individual IND approvals for second doses, streamlining the process for patients showing potential benefit from additional treatment.

Cleveland Clinic Presents Promising Data on Triple-Negative Breast Cancer Vaccine

6 months ago

• Cleveland Clinic researchers presented updated findings on their vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. • The Phase 1 clinical trial showed the investigational vaccine was generally well tolerated and produced an immune response in most patients across three cohorts. • Anixa Biosciences is planning a Phase 2 study to evaluate the efficacy of the vaccine, with the trial expected to begin in 2025 and last approximately two to three years. • The vaccine targets α-lactalbumin, a protein present in most triple-negative breast cancers, prompting the immune system to attack the tumor.

CAR-T Therapy Demonstrates Significant Reduction in Multiple Myeloma Disease Burden

8 months ago

• Data from the CARTITUDE-4 clinical trial indicates that CAR-T therapy shows improved outcomes compared to standard of care for multiple myeloma patients. • Cerebrospinal fluid (CSF) analyses from patients treated with a novel therapy showed over 80% reduction in NAA levels from baseline, suggesting significant therapeutic impact. • Anixa Biosciences received clearance for a single-patient investigational new drug application to redose a patient in a clinical trial, allowing for extended evaluation.